Overall verdict
Sell
1.5/10
1-year performance
-98.81%
Score breakdown
Down 98.8% over 1 year, 0% of the 52-week range.
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial ; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ) ;
and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was formerly known as Enlivex Therapeutics Ltd. and changed its name to Enlivex Ltd. in February 2026. The company was founded in 2005 and is headquartered in Ness Ziona, Israel.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
Israel
CEO
Dr. Oren Hershkovitz Ph.D.
Founded
2005
Employees
34
Revenue / employee
0 USD
Next earnings
December 24, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
27.15 USD
52-week low
0.20 USD
1-year performance
-98.81%
Declining
Year-to-date performance
-98.11%
Declining
Drawdown
-99.24%
Major drawdown
Position in the 52-week range
0% of range
Against the world ETF
Over 12 years, from July 2014 to September 2026, the share did clearly worse than the world ETF once risk is accounted for. It earned less, while shaking 6.5 times harder.
$10,000 placed at the end of July 2014 are worth today
| Enlivex | $2 |
| World ETF | $35,625 |
| S&P 500 | $48,424 |
| Risk-free placement | $12,784 |
The risk
- Shaking:the share moves 6.5 times as much as the world ETF.
- Worst fall:-100 % between August 2014 and September 2026. $10,000 placed at the top fell to $2. The world ETF, at worst: -34 %. The share has not returned to its high yet.
Enlivex earned less than the world ETF since 2014
Value of $10,000 placed at the end of July 2014, dividends reinvested, in dollars
- Enlivex: $2
- World ETF: $35,625
- S&P 500: $48,424
- Risk-free placement: $12,784
Based on past performance. This is not a recommendation.
ROIC -0.7%, ROE 99.2%.
Net margin
—
Sector -223.82%|S&P 13.13%
Gross margin
—
Return on equity (ROE)
99.20%
Exceptional
Sector -58.62%|S&P 16.52%
Return on invested capital (ROIC)
-0.68%
Negative
Free cash flow margin (FCF)
—
Revenue (trailing 12 months)
—
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
3.3/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
0.0x
Cheap
Sector 11.8x|S&P 23.7x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.4x|S&P 15.0x
PEG
0.00
Growth unpriced
Sector -0.01|S&P 0.89
Market cap
4.1M USD
Financial strength
2.6/10Cash covers 32.1% of the debt, gearing 0.3%.
Net debt / EBITDA
—
Gearing (net debt / equity)
0.31%
Stretched
Cash
5.6M USD
Cash / market cap
137.97%
Very solid
Cash / total debt
32.10%
Solid
Net debt
11.9M USD
Equity
3.9Md USD
Closed daily candles, 2 years
Last close on October 16, 2026: 0.21 USD
- MM200.41
- MM500.97
- MM2009.33
- RSI 1411.8
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-12.95%
200-day average slope, 3 months
-31.43%
50-day average slope, 1 month
-61.27%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
5.48 % per day
Volatility change
-6.85%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.15 (1) | -0.75 (1) | 0 (1) | — | -20 (1) |
| 2027 | -0.21 (1) | -11.70 (1) | 0 (1) | — | -25 (1) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of August 3, 2026.
Same sub-industry: 780 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARTV | 6.2 | N/A | 296M USD | Not meaningful (loss) | -36183.7 % | -100.0 % | -35.4 % | 3.6x | -26.0 % | 108.2 % | ||
| 2 | SRZN | 5.5 | 4.3 | 295M USD | Not meaningful (loss) | -3042.9 % | 408.6 % | — | 2.2x | -11.9 % | 83.8 % | ||
| 3 | ANIK | 4.6 | 3.7 | 277M USD | Not meaningful (loss) | -2.6 % | 15.6 % | -1.9 % | -25.9x | 0.2 % | 125.1 % | ||
| 4 | ALERS | 4.6 | 4.8 | 278M USD | 35.3x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.1 % | -0.2 % | ||
| 5 | BNTC | 4.4 | N/A | 295M USD | Not meaningful (loss) | — | — | -33.1 % | 3.5x | -5.9 % | -43.9 % | ||
| 6 | A475830 | 3.2 | 3.3 | 258M USD | 19.4x | 45646.4 % | 479.1 % | 9.5 % | 2.5x | -13.1 % | -50.8 % | ||
| 7 | A376900 | 2.8 | 3.1 | 262M USD | Not meaningful (loss) | -38.7 % | 36.6 % | -161.2 % | -7.1x | -6.4 % | -27.2 % | ||
| 8 | ENLV | 1.5 | N/A | 4.1M USD | 0.0x | — | — | -0.7 % | — | -256.9 % | -98.8 % | ||
| 9 | 4169 | 1.4 | 1.4 | 296M USD | Not meaningful (loss) | -4.5 % | 10.0 % | — | -11.9x | — | -1.0 % |
